ready to pitch
Houston-based medtech company CorInnova is gearing up for what could be a big payday.
CorInnova is among five medtech companies that have been invited to present pitches in October for the National Capital Consortium for Pediatric Device Innovation’s “Make Your Medical Device Pitch for Kids!” competition.
CorInnova and the four other finalists now have access to a four-month pediatric accelerator program led by MedTech Innovator and will vie for a share of $150,000 in grant funding from the U.S. Food and Drug Administration (FDA). The pitch event is part of the 10th annual Symposium on Pediatric Device Innovation.
“Addressing unmet needs across pediatric populations is critical to advancing children’s health, and we are delighted to once again work with pioneering companies that seek to bridge this care gap,” says Kolaeh Eskandanian, president and chief innovation officer at Children’s National Hospital and principal investigator for the pediatric device consortium.
CorInnova has developed a minimally invasive device for the treatment of congestive heart failure. Specifically, CorInnova’s soft, flexible device can be inserted through a 1-inch incision to increase the amount of blood pumping in the heart by 50 percent.
The device’s primary benefit is that there’s no contact with blood, thus minimizing complications when the device is being used. Blood contact during a heart procedure can increase the risk of health problems such as stroke and kidney disfunction.
“The device is collapsible, allowing it to be delivered and secured to the heart in a minimally invasive manner. The device conforms to the heart’s surface, and gently compresses the heart to increase cardiac output using an external pneumatic driver that operates in synchrony with the heartbeat,” CorInnova explains on its website.
In the U.S., around 40,000 babies are born each year with congenital heart defects. About one-fourth of these newborns have critical defects, often prompting the need for surgery or other procedures.
Since being founded in 2004, CorInnova has raised at least $6.3 million, according to Crunchbase. This includes a $6.1 million investment from Wellcome Trust, a London-based charitable foundation that focuses on biomedical research.
Aside from the MedTech Innovator accelerator, CorInnova has participated in the TMC Accelerator’s fall 2019 accelerator program for medical device makers and the fall 2018 gBETA Medtech accelerator program.
The four other finalists in the medtech pitch competition are:
- La Palma, California-based Innovation Lab, whose mechanical elbow brace stabilizes tremors in some pediatric patients with cerebral palsy.
- Biddeford, Maine-based Prapela, whose vibrating pad helps treat apnea in newborns.
- Richmond, Virginia-based Tympanogen, whose nonsurgical procedure takes the place of surgery for eardrum repair.
- Xpan of Concord, Ontario, Canada, whose universal trocar (a surgical instrument) improves safety, access, and flexibility during various procedures.